Mammoth Biosciences has appointed Peter Nell as chief business officer and head of therapeutics, and has named Ted Tisch chief operations officer.
Nell has previously served in various positions at Casebia Therapeutics and Bayer HealthCare. In his new role at Mammoth, he will scale the company's CRISPR offerings. Nell is a chemist by training, and is listed as co-inventor on more than 45 patents, and author or co-author of several scientific publications and book contributions in the biomedical field.
Tisch joins Mammoth after four years at Synthego, where he established the product development, manufacturing operations, and commercial program for two CRISPR-based product lines. He previously served as vice president and general manager for Bio-Rad Laboratories' protein function division.